Business
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children Paris and Tarryt
About this update from Sanofi Sa
[{"type":"image","alt":"Sanofi Winthrop Industrie","displaySize":"","headline":null,"caption":"Sanofi Winthrop Industrie","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/njIuMc8eT.GfUOY8hGPCUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137","width":300,"height":84}},"lazy":false},{"type":"text","content":"Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment ","length":156,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children","length":136,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":325,"olType":false},{"type":"text","content":"Paris and Tarrytown, February 27, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the EU for the treatment of chronic spontaneous urticaria (CSU). This recommendation covers children aged two to 11 years with moderate-to-severe CSU, an inadequate response to histamine-1 antihistamines (H1AH), and who are naïve to anti-immunoglobulin E (IgE) therapy for CSU. A final decision is expected in the coming months.","length":534,"tagName":"p"},{"type":"text","content":"The positive CHMP opinion in young children is supported by data from the LIBERTY-CUPID clinical study program, including two phase 3 studies, Study A and Study C, in which children aged six to 11 years participated (clinical study identifier: NCT04180488), and the single-arm, CUPIDKids phase 3 study (clinical study identifier: NCT05526521) in children aged two to 11 years with CSU.","length":385,"tagName":"p"},{"type":"text","content":"Dupixent is approved for CSU in certain ...